{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 26,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a visual comparison between a 'cold' antibody and the 'hot' FPI-1434 conjugate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/17",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.4,
        "y": 0.6
      },
      "kind": "image",
      "text": "Visual comparison of cold vs hot antibody",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0b0ffc0-23b8-44a1-a21c-dc9891f8d5cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Using alpha emitters in place of chemical toxins in ADCs represents a significant yet untapped opportunity. Alphas also have the potential to “resurrect” naked antibodies which can target, but not effectively kill, cancer cells.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08472ef6-7a4c-4973-99fb-856cbd2c11ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.43
      },
      "kind": "list",
      "text": "IGF-1R: Well-established cancer biomarker found on most solid tumors where blocking the target failed to stop tumor growth",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5aac93b3-4657-4406-a554-1694ab725998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "Fusion’s initial approach involved dosing with the highest possible concentration of radiolabeled antibody. We observed toxicity (thrombocytopenia) at higher doses inhibiting delivery of multiple cycles. Fusion’s second dosing regimen involved pre-administration of a small amount (0.5 mg/kg) of the parent (cold) antibody to reduce off-tumor binding. Results showed improved safety and biodistribution.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f144bf12-40b5-4e46-b64c-ea619a07f450",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-1434 Phase 1 Trial: A First-of-its-Kind Antibody-Based Targeted Alpha Therapy Study for Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "344662b9-29f1-43ea-b104-6f19c82cda00",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 17,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d2860898-6698-492a-878a-e8ba168bf1e1",
      "evidence": "The document presents results for the FPI-1434 Phase 1 Trial, including encouraging safety and early signals of antitumor activity",
      "position": 1,
      "objective": "Present promising results for FPI-1434 Phase 1 Trial",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}